Exchange: NASDAQ·Updated 07:44 PM EST
RLAY logo

RLAY Relay Therapeutics Inc

$15.80
$0.21
(1.32%)
Today
Closed $16.12
$0.32
(1.99%)
After Hours
Reported EarningsNov 4
Mkt Cap$3.56B
Vol3.98M

About RLAY

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
50

Neutral Sentiment

How do you feel about RLAY?

topstockalerts
Relay Therapeutics receives an Overweight rating from JPMorgan, with a $31 price target, reflecting the bank's confidence in its oncology pipeline and the commercial potential of its lead drug candidate, zovegalisib. The company is developing this PI3Kα inhibitor for patients with PI3Kα-mutated breast cancer, as well as vascular anomalies. JPMorgan's physician surveys indicate that approximately 60%–70% of patients with second-line or later PI3Kα-mutated breast cancer could be eligible for treatment with zovegalisib, suggesting a potentially broad patient population. Phase 1/2 clinical results showed a median progression-free survival of 11.1 months and an objective response rate of 43%, supporting further development of the drug. Beyond breast cancer, JPMorgan sees a substantial additional opportunity in vascular anomalies, estimating a total addressable market of more than $5 billion and assigning a high probability of clinical and commercial success to the program. $RLAY
FavorableInvestors
$RLAY Swing recap — target tagged, closing the loop. Plan posted Fri Oct 23: long shares, entry $18.11 (zone $18.00–$18.10), target $18.98, stop $17.63. I entered Mon Oct 26 — 7 shares at ~$18.15. Why it surfaced: a demand-zone scan caught the V-recovery off the $16.22 October low — a higher-low reclaim into a defended $17.90–$18.10 shelf. Data behind it: $911M cash with runway guided into 2029, so no financing overhang in the window; analyst panel 13-for-13 Buy-rated with a $28 median target; institutional ownership about 97%. What happened: price dipped to $17.68 Friday — just above the stop — pressed to $18.96 Tuesday (2 cents short), then ran through the $18.98 target Wednesday to a $19.705 high, closing at $19.69. Stop never tagged. Just the plan, posted before and after — no guarantees.

Advertisement|Remove ads.